Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue

Journal of Mammary Gland Biology and Neoplasia

Volumn 17, Issue 2, 2012, Pages 155-164

  Liu, Ning Qing ^a,b   Braakman, René B H ^a,c   Stingl, Christoph ^a   Luider, Theo M ^a   Martens, John W M ^a,c   Foekens, John A ^a,b,c   Umar, Arzu ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Proteomics Center   (Netherlands)

^c Center for Translational Molecular Medicine   (Netherlands)

Author keywords

Breast cancer; Data analysis; Estrogen receptor associated proteins; High resolution mass spectrometry; Label free proteomics

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PEPTIDE; PROGESTERONE RECEPTOR; PROTEIN; PROTEOME;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER TISSUE; CELL DIVISION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MASS SPECTROMETRY; NANOANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TISSUE SECTION;

BREAST NEOPLASMS; CELL SEPARATION; DOWN-REGULATION; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LASER CAPTURE MICRODISSECTION; MAMMARY GLANDS, HUMAN; NEOPLASM PROTEINS; PEPTIDE MAPPING; PEPTIDES; PROTEOMICS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84865793194     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-012-9252-6     Document Type: Article

References (27)

1. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009;8(6):1278-94.
2. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996;274(5289):998-1001. (Pubitemid 26398425)
3. Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. Nat Protoc. 2006;1(2):586-603.
4. Umar A, Luider TM, Foekens JA, Pasa-Tolic L. NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells. Proteomics. 2007;7(2):323-9. (Pubitemid 46188242)
5. Braakman RB, Tilanus-Linthorst MM, Liu NQ, Stingl C, Dekker LJ, Luider TM, et al. Optimized nLC-MS workflow for laser capture microdissected breast cancer tissue. J Proteom. 2012. doi:10.1016/j.jprot.2012.01.022.
6. Umar A, Dalebout JC, Timmermans AM, Foekens JA, Luider TM. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisationtime of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics. 2005;5 (10):2680-8. (Pubitemid 40966495)
7. Braakman RB, Luider TM, Martens JW, Foekens JA, Umar A. Laser capture microdissection applications in breast cancer proteomics. Methods Mol Biol. 2011;755:143-54.
8. Stingl C, van Vilsteren FG, Guzel C, Ten Kate FJ, Visser M, Krishnadath KK, et al. Reproducibility of protein identification of selected cell types in Barrett's esophagus analyzed by combining laser-capture microdissection and mass spectrometry. J Proteome Res. 2011;10(1):288-98.
9. Cox J,MannM. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367-72.
10. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda -A peptide search engine integrated into the Max-Quant environment. J Proteome Res. 2011;10(4):1794-805.
11. Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN, Camp 2nd DG, et al. DAnTE: A statistical tool for quantitative analysis of -omics data. Bioinformatics (Oxford, England). 2008;24(13):1556-8. (Pubitemid 351911716)
12. Daly DS, Anderson KK, Panisko EA, Purvine SO, Fang R, Monroe ME, et al. Mixed-effects statistical model for comparative LC-MS proteomics studies. J Proteome Res. 2008;7(3):1209-17.
13. Karpievitch YV, Taverner T, Adkins JN, Callister SJ, Anderson GA, Smith RD, et al. Normalization of peak intensities in bottomup MS-based proteomics using singular value decomposition. Bioinformatics (Oxford, England). 2009;25(19):2573-80.
14. Karpievitch Y, Stanley J, Taverner T, Huang J, Adkins JN, Ansong C, et al. A statistical framework for protein quantitation in bottomup MS-based proteomics. Bioinformatics (Oxford, England). 2009;25(16):2028-34.
15. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics. 2005;4(12):2010-21. (Pubitemid 41830195)
16. Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, et al. A practical guide to the MaxQuant computational platform for SILACbased quantitative proteomics. Nat Protoc. 2009;4(5):698-705.
17. Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 2010;32(2):279-89.
18. Clough T, Key M, Ott I, Ragg S, Schadow G, Vitek O. Protein quantification in label-free LC-MS experiments. J Proteome Res. 2009;8(11):5275-84.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate -A practical and powerful approach to multiple testing. J R Stat Soc Ser B-Methodol. 1995;57(1):289-300.
20. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 2003;63(17):5203-8. (Pubitemid 37139828)
21. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18(1):26-35. (Pubitemid 40128091)
22. da Silva BB, dos Santos AR, Pires CG, Correa-Lima MA, Pereira-Filho JD, dos Santos LG, et al. E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. Eur J Gynaecol Oncol. 2010;31(1):90-3.
23. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103(2):249-55.
24. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107(14):6340-5.
25. Gruvberger S, Ringner M, Chen YD, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001;61 (16):5979-84. (Pubitemid 32762524)
26. Barnett DH, Sheng S, Charn TH, Waheed A, Sly WS, Lin CY, et al. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res. 2008;68(9):3505-15.
27. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol. 2011;32(3):441-50.